Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Atsuhiko Yoshizawa"'
Autor:
Takuya Tsujino, Satoshi Tokushige, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Masanobu Saruta, Takaya Ohno, Keita Nakamori, Ryoichi Maenosono, Kazuki Nishimura, Shogo Yamazaki, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Fumihiko Urabe, Shunsuke Tsuzuki, Kosuke Iwatani, Shutaro Yamamoto, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma
Publikováno v:
Cancer Medicine, Vol 12, Iss 19, Pp 19414-19422 (2023)
Abstract Background There is little evidence of abiraterone acetate (AA) plus prednisone for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC). In this study, we conducted a comparative analysis of real‐world survival o
Externí odkaz:
https://doaj.org/article/a557172dfc5b4cd6bd24118ee1dcb769
Autor:
Keita Nakamori, Shogo Yamazaki, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Takaya Ohno, Yusuke Yano, Kazuki Nishimura, Satoshi Tokushige, Taizo Uchimoto, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Jun Miki, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 39, Iss , Pp 100558- (2023)
Background and Purpose: Pembrolizumab has now become a standard of care in metastatic urothelial carcinoma (mUC), although the treatment effect of the drug substantially differs among individuals. Emerging evidence suggests that radiotherapy exerts a
Externí odkaz:
https://doaj.org/article/877ddcfd04d44768b095e546d59fd5f7
Autor:
Atsuhiko Yoshizawa, Kiyoshi Takahara, Masanobu Saruta, Kenji Zennami, Takuhisa Nukaya, Kosuke Fukaya, Manabu Ichino, Naohiko Fukami, Atsuko Niimi, Hitomi Sasaki, Mamoru Kusaka, Motoshi Suzuki, Makoto Sumitomo, Ryoichi Shiroki
Publikováno v:
Prostate International, Vol 9, Iss 1, Pp 18-24 (2021)
Background: Disease progression in castrate-resistant prostate cancer (PCa) is most commonly driven by the reactivation of androgen receptor (AR) signaling and involves AR splice variants including ARV7. Materials and methods: We used the ARV7-positi
Externí odkaz:
https://doaj.org/article/061896de725d436bb21eb5a5968eee81
Autor:
Takuhisa Nukaya, Kiyoshi Takahara, Atsuhiko Yoshizawa, Masanobu Saruta, Yusuke Yano, Takaya Ohno, Taizo Uchimoto, Wataru Fukuokaya, Takahiro Adachi, Shogo Yamazaki, Satoshi Tokushige, Kazuki Nishimura, Takuya Tsujino, Keita Nakamori, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki
Publikováno v:
Clinical Genitourinary Cancer; Feb2024, Vol. 22 Issue 1, p76-83, 8p
Autor:
Taizo Uchimoto, Tatsuo Fukushima, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Takeshi Hashimoto, Atsuhiko Yoshizawa, Ko Nakamura, Yusuke Yano, Kazuki Nishimura, Kyosuke Nishio, Keita Nakamori, Kosuke Iwatani, Shutaro Yamamoto, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Jun Miki, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Shin Egawa, Haruhito Azuma
Publikováno v:
BJU internationalReferences.
To assess the real-world clinical benefit of re-challenging chemotherapy after pembrolizumab in patients with metastatic urothelial carcinoma (mUC), as there have been several reports suggesting that programmed cell death protein-1/programmed death-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c091182af6da45cc3b28f9bffe791a3
https://pubmed.ncbi.nlm.nih.gov/36098556
https://pubmed.ncbi.nlm.nih.gov/36098556
Autor:
Keita Nakamori, Shogo Yamazaki, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Takaya Ohno, Yusuke Yano, Kazuki Nishimura, Satoshi Tokushige, Taizo Uchimoto, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Jun Miki, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma
Publikováno v:
Clinical and translational radiation oncology. 39
Pembrolizumab has now become a standard of care in metastatic urothelial carcinoma (mUC), although the treatment effect of the drug substantially differs among individuals. Emerging evidence suggests that radiotherapy exerts a synergistic effect with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7d24c84285a5547d9c504b3d6e28759
https://pubmed.ncbi.nlm.nih.gov/36545361
https://pubmed.ncbi.nlm.nih.gov/36545361
Autor:
Masanobu Saruta, Kiyoshi Takahara, Atsuhiko Yoshizawa, Atsuko Niimi, Toshiyuki Takeuchi, Takuhisa Nukaya, Masashi Takenaka, Kenji Zennami, Manabu Ichino, Hitomi Sasaki, Mamoru Kusaka, Motoshi Suzuki, Makoto Sumitomo, Ryoichi Shiroki
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 18; Pages: 5466
Alanine-serine-cysteine transporter 2 (ASCT2) has been associated with increased levels of metabolism in various malignant tumors. However, its biological significance in the proliferation of prostate cancer (PCa) cells remains under investigation. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2deff98119ed67d1ddd920750af1c5d
https://pubmed.ncbi.nlm.nih.gov/36143113
https://pubmed.ncbi.nlm.nih.gov/36143113
Autor:
Yoshinari Muto, Makoto Sumitomo, Masanobu Saruta, Atsuhiko Yoshizawa, Kiyoshi Takahara, Ryoichi Shiroki
Publikováno v:
Journal of Urology. 207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80b6892d2f23392fc39bc819b0329bad
https://doi.org/10.1097/ju.0000000000002516.03
https://doi.org/10.1097/ju.0000000000002516.03
Autor:
Atsuhiko Yoshizawa, Kosuke Fukaya, Kenji Zennami, Masanobu Saruta, Takuhisa Nukaya, Hitomi Sasaki, Makoto Sumitomo, Ryoichi Shiroki, Mamoru Kusaka, Manabu Ichino, Atsuko Niimi, Kiyoshi Takahara, Motoshi Suzuki, Naohiko Fukami
Publikováno v:
Prostate International
Prostate International, Vol 9, Iss 1, Pp 18-24 (2021)
Prostate International, Vol 9, Iss 1, Pp 18-24 (2021)
Background Disease progression in castrate-resistant prostate cancer (PCa) is most commonly driven by the reactivation of androgen receptor (AR) signaling and involves AR splice variants including ARV7. Materials and methods We used the ARV7-positive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52cc2fec2c258ffc034e7d611f5a0db5
http://europepmc.org/articles/PMC8053692
http://europepmc.org/articles/PMC8053692
Autor:
Yusuke Yano, Takaya Ohno, Kazumasa Komura, Wataru Fukuokaya, Taizo Uchimoto, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Shogo Yamazaki, Satoshi Tokushige, Kazuki Nishimura, Takuya Tsujino, Keita Nakamori, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Jun Miki, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma
Publikováno v:
Cancers; Volume 14; Issue 22; Pages: 5659
Serum C-reactive protein (CRP) is known to be a biomarker for systemic inflammatory reactions. In the present study, we sought to measure the predictive value of serum CRP level for metastatic renal cell carcinoma (mRCC) treated with first-line ipili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d6cdcd51a3e5644d3aad6dee0581148
https://doi.org/10.3390/cancers14225659
https://doi.org/10.3390/cancers14225659